Trials / Active Not Recruiting
Active Not RecruitingNCT05378100
Ketamine for Multiple Sclerosis Fatigue
Low-Dose Ketamine Infusion for the Treatment of Multiple Sclerosis Fatigue (INKLING-MS)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Johns Hopkins University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketamine | Infusion of ketamine 0.5 mg/kg over 40 minutes |
| DRUG | Midazolam | Infusion of midazolam 0.05 mg/kg over 40 minutes |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2026-06-01
- Completion
- 2026-10-01
- First posted
- 2022-05-18
- Last updated
- 2026-03-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05378100. Inclusion in this directory is not an endorsement.